コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ctible health plans, 12.1 operations/100,000 enrollees).
2 eby the program's environmental benefits per enrollee.
3 were collected and tested from 2885 (78%) of enrollees.
4 viral therapy (ART) reinitiation in Medicaid enrollees.
5 All communities contributed >/=20 enrollees.
6 dermatologists is often limited for Medicaid enrollees.
7 %-64%) at 1 year post discharge among Part D enrollees.
8 ation-level health indicators among Medicare enrollees.
9 Informed consent was obtained from potential enrollees.
10 mary care for the growing number of Medicaid enrollees.
11 oss Blue Shield of Texas [BCBSTX]) for Texas enrollees.
12 SUD treatment facilities that serve Medicaid enrollees.
13 nly if an infrastructure exists to serve new enrollees.
14 exists across local communities to serve new enrollees.
15 are fee-for-service and commercially insured enrollees.
16 -based treatment infrastructure for Medicaid enrollees.
17 of death among antiretroviral therapy (ART) enrollees.
18 Infection was confirmed in 60 of 66 (91%) enrollees.
19 e scope of medical services required for new enrollees.
20 fitness benefits than among the 4097 earlier enrollees.
21 on rates are primarily derived from Medicare enrollees.
22 ith healthier enrollees to plans with sicker enrollees.
23 % CI, 4.4 to 11.7), as compared with earlier enrollees.
24 was the least common, being reported in 167 enrollees.
25 have predominantly been reported in Medicare enrollees.
26 y insured individuals and Medicare Advantage enrollees.
27 gth of stay and these outcomes among hospice enrollees.
28 ries-related treatment visits among Medicaid enrollees.
29 l therapy was identified from all Medicare D enrollees.
30 %); MRI use increased from 17 to 65 per 1000 enrollees, 10% annual growth (95% CI, 3.3%-16.5%); and u
37 ribing daily hospital admissions of Medicare enrollees (23.7 million fee-for-service beneficiaries [a
39 edicine use decreased from 32 to 21 per 1000 enrollees, 3% annual decline (95% CI, 7.7% decline to 1.
48 ical data were obtained prospectively in 146 enrollees (73+/-10 years) undergoing dual chamber pacema
49 dominant modality of diagnosis in all RIETE enrollees (78.2% [99% CI, 77.6-78.7]); including pregnan
51 uating rates of bariatric procedures/100,000 enrollees, 90-day mortality, readmission rate and paymen
52 dditional annual hospital admissions per 100 enrollees (95% CI, 1.8 to 2.6), 13.4 more annual inpatie
53 .6), 13.4 more annual inpatient days per 100 enrollees (95% CI, 10.2 to 16.6), and an increase of 0.7
54 19.8 fewer annual outpatient visits per 100 enrollees (95% confidence interval [CI], 16.6 to 23.1),
58 are Advantage enrollees, this study assesses enrollee adoption by type of benefit (eg, caregiver supp
59 sured patients aged 45-64 years and Medicare enrollees after 2012, although at half the prior rate (i
60 ospective cohort study of Tennessee Medicaid enrollees age >=18 years initiating long-acting opioids
61 to rates among noninstitutionalized Medicare enrollees age 65 and older undergoing the same procedure
65 assessed in 87,736 fee-for-service Medicare enrollees aged 65 years or older diagnosed with advanced
67 mortality among Cardiovascular Health Study enrollees aged 65-98 years who, at baseline assessment i
71 proved appointment availability for Medicaid enrollees among participating providers without generati
73 2.3 million to reimburse care provided to MA enrollees and collected $9.4 million (18% of the billed
74 iven low rates of hospice use among Medicaid enrollees and considerable evidence of suffering at the
77 eadmission for AMI or stroke) between Part D enrollees and nonenrollees, after adjustment for patient
79 ve access to dermatology care among Medicaid enrollees and played an especially important role for th
80 plans, the differences between the 1154 new enrollees and the 3910 earlier enrollees were 1.5 percen
81 sing numbers and diversity of medical school enrollees and the US physician workforce size and compos
82 rcial claims, rates were calculated per 1000 enrollees, and trends were reported over time in aggrega
83 ternatively, enrollment costs can dampen per-enrollee benefits if their correlation with status-quo c
84 m 1380 to 1945 biopsies per 100,000 Medicare enrollees between 1997 and 2008, which represents a comp
85 ncreased from 693.9 to 947.2 visits per 1000 enrollees between 1999 and 2007 (rate difference, 253.3;
86 fertilization (IVF) rates among health plan enrollees between 2012 and 2017 after a large US empoloy
88 nd the representativeness of the SHIFT trial enrollees compared with those in the Swedish Heart Failu
91 and 2002, respectively) for two groups: FEHB enrollees diagnosed in 1999 with bipolar disorder, major
93 d from 2001 to 2013 (664 to 1058 per 100,000 enrollees), driven by HCV and nonalcoholic fatty liver d
95 nd continued to provide SOC practices to all enrollees: enhanced contact with interventionist (EC) (b
97 her than among noninstitutionalized Medicare enrollees for all procedures (surgery for bleeding duode
98 urred higher expenditures for commercial HMO enrollees for professional, hospital, laboratory, pharma
100 d >/=65 years] per year; 85% of all Medicare enrollees) for the period 1999 to 2010 in 1943 counties
101 ed seventy-seven eligible PCPs of consenting enrollees from 8 regional or urban Ontario CR programs w
102 mmercially insured and Medicare managed care enrollees from a large, national US managed care health
103 udy (GHS) cohort that included 4335 eligible enrollees from among 5000 subjects who participated in t
107 for dementia, AD, and PD among all Medicare enrollees >/= 65 years in 50 northeastern U.S. cities (1
108 cular and respiratory disease among Medicare enrollees >/= 65 years of age during the 12-year period
110 ared with white participants, Asian-American enrollees had a 177% increased risk of developing MH (ad
111 aged-care plan for at least 4 years in which enrollees had at least 2 visits to an eye care provider
112 th acute conjunctivitis by ophthalmologists, enrollees had considerably higher odds of antibiotic pre
116 pulations in other states, Massachusetts AQC enrollees had lower spending growth and generally greate
117 Results In almost all instances, Medicare enrollees had the highest utilization rate for each moda
120 to a sustained period of slow growth in per-enrollee health care spending and improvements in health
121 costs can increase a program's benefits per enrollee if they are systematically higher for (and thus
123 .4% (from 3.2 procedures per 10,000 Medicare enrollees in 1991 to 5.1 procedures per 10,000 in 2010).
124 2% (from 31.2 procedures per 10,000 Medicare enrollees in 1991 to 62.1 procedures per 10,000 in 2010)
125 ; CT examinations increased from 52 per 1000 enrollees in 1996 to 149 per 1000 in 2010, 7.8% annual i
127 ferral region rates of PCI per 1000 Medicare enrollees in 2007 on the regions' rates of providing >/=
129 neurologic and allergic adverse events among enrollees in 8 medical care organizations (the Vaccine S
130 For every additional optometrist per 100 000 enrollees in a community, the hazard of surgery increase
132 s nested case-control study was among female enrollees in a large U.S. integrated health care deliver
139 increased copayments for ambulatory care and enrollees in matched control plans--similar plans that m
141 t the increased use of prescription drugs by enrollees in Medicare Part D has had on spending for oth
142 use of outpatient and inpatient care between enrollees in Medicare plans that increased copayments fo
143 ge annual medical spending on claims for the enrollees in organizations that entered the AQC in 2009
144 interval [CI], 2.6 to 9.7) among the 755 new enrollees in plans that added fitness benefits than amon
145 usted absolute differences in proportions of enrollees in the 2 years, 7.9 percentage points and 10.3
149 ps in 2009, but the increase was smaller for enrollees in the intervention group--$15.51 (1.9%) less
152 an increase in the vitrectomy rates per 1000 enrollees in this large managed care network over the co
157 a variety of strategies affecting potential enrollees, insurers, and healthcare providers are offere
158 federal financial assistance for Marketplace enrollees, introducing a public plan option in areas lac
159 during screening mammography among Medicare enrollees is associated with increased DCIS incidence, t
160 nts for ambulatory care were magnified among enrollees living in areas of lower income and education
161 ing a high volume of surgical care for their enrollees may benefit by critically evaluating the syste
162 various racial and ethnic groups of Medicare enrollees may contribute to persistent disparities in he
163 7.6 years) with newly diagnosed XFG and 7339 enrollees (median age 77.3 years) with newly diagnosed P
167 tigated the impact of Mutuelles' coverage on enrollees' medical care utilization using logistic regre
171 is conducted among 18- to 49-year-old female enrollees of a large health care system in western Washi
172 82) and non-Hispanic white (NHW; n = 82,696) enrollees of Kaiser Permanente Northern California (KPNC
174 spital admissions among 9.2 million Medicare enrollees of the Northeast/Mid-Atlantic United States be
175 Trained field staff posed as either Medicaid enrollees or privately insured enrollees seeking new-pat
176 but not top quintile of facility to Medicaid enrollee per capita ratio), or high access (ie, top quin
178 ding on claims grew an average of $62.21 per enrollee per quarter less than it did in the control coh
179 e 2000s through early 2010s (images per 1000 enrollees per year for Medicare: -301 [95% CI: -510, -92
180 ough at half the prior rate (images per 1000 enrollees per year for Medicare: 17 [95% CI: 6, 28]; com
181 rough the mid to late 2000s (images per 1000 enrollees per year for Medicare: 91 [95% confidence inte
183 has reached 28% (n = 17,065) of the targeted enrollee population and more than 2 million biological s
184 regression assessed factors associated with enrollees' prescription of >/=1 glaucoma medication clas
187 onic Renal Insufficiency Cohort (CRIC) study enrollees recruited from Kaiser Permanente Northern Cali
188 r of gastroenterology procedures per million enrollees remained largely unchanged in Medicare patient
191 Main Outcomes and Measures: Proportion of enrollees requiring additional LTPs, hazard ratio with 9
192 ion classes prescribed and the proportion of enrollees requiring cataract or glaucoma surgery within
196 ther Medicaid enrollees or privately insured enrollees seeking new-patient primary care appointments.
199 these findings in a nonrandomized subset of enrollees show an HLA-specific vaccine effect on the tim
202 t entered the AQC in 2009 was $461 lower per enrollee than spending in the control states (P<0.001),
203 sharing, such as PPOs (20 operations/100,000 enrollees) than in HDHPs (high-deductible health plans,
206 aling file, if there was a claim against the enrollee there was a narrative regarding each malpractic
207 available to HMO and PPO Medicare Advantage enrollees, this study assesses enrollee adoption by type
209 btained from January 26, 2012 (date of first enrollee), through May 1, 2015, to establish participant
210 spending increased from a mean of $2802 per enrollee to $3610 during this period (29% increase).
211 decrease in inpatient spending from $641 per enrollee to $373 and was driven primarily by an increase
212 11 were substantially less likely than white enrollees to have adequate control of blood pressure (ad
214 The estimated VA health care costs for MA enrollees totaled $13.0 billion over 6 years, increasing
215 nt disorder (N=19,094) and privately insured enrollees unaffected by the policy in a comparison natio
218 and blacks were underrepresented relative to enrollees undergoing eye care for reasons other than cor
221 d previously demonstrated savings among BCBS enrollees varied similarly across settings, services, an
222 All-cause 30-day death was more common among enrollees versus nonenrollees (4.0% versus 3.3%), but th
224 pes, the average wait time for Medicaid-CHIP enrollees was 22 days longer than that for privately ins
227 ess to provide appointments for new Medicaid enrollees was related to the size of increases in Medica
228 duced spending and improved quality for BCBS enrollees, was also associated with changes in spending
230 the 1154 new enrollees and the 3910 earlier enrollees were 1.5 percentage points or less for each me
234 s, participants enrolled at sites with fewer enrollees were at higher risk for adverse outcomes (HR:
238 m 16 clinical research sites in 8 countries, enrollees were interviewed to assess willingness to take
244 ontrol doses received the best dose, and new enrollees were randomly assigned to receive 200 IU/d or
246 how representative RELAX-AHF clinical trial enrollees were to those patients with AHF found in inter
248 There was no difference in the proportion of enrollees who developed adverse events after keratoplast
250 reas of lower income and education and among enrollees who had hypertension, diabetes, or a history o
252 idence of initial opioid prescriptions among enrollees who had not used opioids declined by 54%, from
260 incidence was estimated as the percentage of enrollees who received an initial opioid prescription am
261 e (1.2 mSv vs 2.3 mSv) and the proportion of enrollees who received high (>20-50 mSv) exposure (1.2%
262 d care network were analyzed to identify all enrollees who underwent 1 vitrectomy or more each year f
266 f 0.7 percentage points in the proportion of enrollees who were hospitalized (95% CI, 0.51 to 0.95),
267 ystem (intervention group) and for 1,351,446 enrollees whose PCPs were not in the system (control gro
269 006 through 2016, we compared spending among enrollees whose physician organizations entered the AQC
270 We analyzed 2006-2009 claims for 380,142 enrollees whose primary care physicians (PCPs) were in t
271 ording to the ZIP Code of residence for each enrollee with the use of previously validated prediction
272 d included Medicare and commercial insurance enrollees with a new, adjudicated prescription for any o
275 cohorts that had a disproportionate share of enrollees with chronic mental health and medical conditi
277 nic health record data, was used to identify enrollees with continuous enrollment in the database for
278 ring a 10-year period, spending for Medicaid enrollees with depression increased substantially, with
282 e containing more than 1000 eyes of Medicare enrollees with glaucoma who underwent LTP in Oklahoma fr
288 dence interval [CI], $33 to $50) (74%) among enrollees with no previous drug coverage, $27 higher (95
291 at the initial LTP was 77.7 (7.5) years for enrollees with ophthalmologist-performed LTP and 77.6 (8
293 community-dwelling, nonelderly disabled dual enrollees with schizophrenia (n = 5554) or bipolar disor
294 of elderly beneficiaries: Medicare Advantage enrollees with stable, uncapped, employer-based drug cov
296 resulted in increased radiation exposure for enrollees, with a doubling in the mean per capita effect
297 demographics and comorbidities to a Medicare enrollee without cancer, and each pair was followed thro
299 medical comorbidities to a group of Medicare enrollees without cancer, and each pair was followed thr
300 ased hazard of developing BRVO compared with enrollees without HTN (aHR, 2.07; CI, 1.75-2.45; P < 0.0